Skip to main content

Table 1 Characteristics of the case and control groups

From: Risk factors for cancer development in type 2 diabetes: A retrospective case-control study

Parameter Malignancy No malignancy P value*
Age at index time (years) (mean ± SD) 67.1 ± 9.7 67.1 ± 9.7 -
  < 65 years (n) 62 (30.5 %) 62 (30.5 %)  
  ≥ 65 years (n) 141 (69.5 %) 141 (69.5 %)  
Gender    -
 male (n) 88 (43.3 %) 88 (43.3 %)  
 female (n) 115 (56.7 %) 115 (56.7 %)  
Place of residence    0.264
 rural (n) 38 (18.7 %) 44 (21.7 %)  
 cities <50,000 inhabitants (n) 27 (13.3 %) 36 (17.7 %)  
 cities >50,000 inhabitants (n) 138 (68.0 %) 123 (60.6 %)  
Smoking habits    0.838
 never smokers (n) 115 (56.7 %) 117 (57.6 %)  
 former smokers (n) 54 (26.6 %) 57 (28.1 %)  
 current smokers (n) 33 (16.3 %) 29 (14.3 %)  
 unknown status (n) 1 (0.5 %) -  
BMI (kg/m2) (mean ± SD) 30.8 ± 5.3 30.1 ± 4.7 0.103
 Comorbidities
  cardiovascular disease (n) 50 (24.6 %) 58 (28.6 %) 0.369
  hypertension (n) 177 (87.2 %) 179 (88.2 %) 0.763
  hyperlipidemia (n) 153 (75.4 %) 159 (78.3 %) 0.480
Diabetes duration (years) (mean ± SD) 10.7 ± 7.4 10.3 ± 8.1 0.262
HbA1c (%) (mean ± SD) 7.39 ± 1.21 % 7.30 ± 1.06 % 0.755
 Antidiabetic medications
  metformin (n) 126 (62.1 %) 167 (82.3 %) <0.001
  sulfonylurea (n) 83 (40.9 %) 101 (49.8 %) 0.090
  acarbose (n) 18 (8.9 %) 14 (6.9 %) 0.581
  DPP-4 inhibitor (n) 11 (5.4 %) 6 (3.0 %) 0.322
  insulin (n) 110 (54.2 %) 81 (39.9 %) 0.005
  insulin dose (IU/kg/24 h) (mean ± SD) 0.59 ± 0.31 0.53 ± 0.24 0.407
  insulin duration (years) (mean ± SD) 6.2 ± 5.6 6.5 ± 4.9 0.529
Aspirin use (n) 102 (52.6 %) 102 (52.8 %) 0.957
 unknown status 9 10  
  1. NS non significant
  2. * between malignancy and non-malignancy groups
\